OncoTherapy Science, Fuso Pharmaceutical Industries Jointly Undertake Phase I Clinical Trial of Anglogenesis Inhibitor OTS102.Tokyo, Japan, Mar 31, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - OncoTherapy Science and Fuso Pharmaceutical Industries jointly announced on March 29 that the Pharmaceuticals and Medical Devices Agency (PMDA PMDA Plastics Machinery Distributors' Association (United Kingdom) PMDA Plutonium Management and Disposition Agreement (US-Russia) PMDA Pharmaceuticals and Medical Device Agency (Japan) ) has accepted a notification of the phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I plan of OTS See Office of Thrift Supervision. 102, an angiogenesis inhibitor currently under development by OncoTherapy Science. Accordingly, OncoTherapy Science plans to conclude a contract with medical institutions and begin registering patients in the trial. OTS102, which consists of VEGF-R2 protein, can inhibit blood vessels from growing out of a solid tumor. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion